ViVita's patented platform technology—the SPEAR Process—removes the immunological barriers from animal-derived tissues. The resultant biomaterial—the BARE Patch—is immune-compatible for use in human patients and provides the body a blueprint for regeneration. Leveraging this technology, ViVita aims to generate off-the-shelf tissue and organ replacements that avoid long-term medication, repeat transplants, and associated patient deaths.
Our Vision
ViVita is at the forefront of the emerging tissue engineering and regenerative medicine market. ViVita aims to apply our novel, patented technology—the SPEAR Platform—to produce a spectrum of xenogeneic extracellular matrix (ECM)-based tissue and organ replacement products.
Our Mission
ViVita's mission is to address the unmet clinical need for replacement tissues and organs by providing off-the-shelf, animal-derived biomaterial products. ViVita's immune-compatible, regenerative products become the patient's own tissues following implantation, thereby providing patients a life-long cure.